Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Clinical Infectious Diseases · 25.01.2024 · 78 (1) · 98-110
DOI: 10.1093/cid/ciad495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.08.2023. Verfasst von Mattia Berton und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerla…. Hauptthemen laut MEDLINE: Obesity, Morbid, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Foundation.
Abstract (Originalsprache)
Background
Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However, this has not been thoroughly evaluated given that obese PWH are underrepresented in clinical trials. We performed virtual trials using physiologically based pharmacokinetic (PBPK) modelling combined with observed clinical data to provide ARV dosing guidance in obese individuals.
Methods
Each trial included a cohort of virtual adults with a body mass index (BMI) between 18.5 and 60 kg/m2. Therapeutic drug-monitoring data from the Swiss HIV Cohort Study (SHCS) were used to verify the predictive performance of the model. Subsequently, the model was applied to predict the pharmacokinetics of ARVs for different obesity classes. The association between ARV plasma concentrations and virological response was investigated in obese and nonobese individuals.
Results
The PBPK model predicted an average reduction in ARV exposure of ∼20% and trough concentrations of ∼6% in obese (BMI ≥30 kg/m2) compared with nonobese (BMI: 18.5–25 kg/m2) individuals, consistent with observed clinical data. Etravirine and rilpivirine were the most impacted, especially in individuals with BMI >40 kg/m2 whose trough concentrations were below the clinical target threshold. Obese PWH in the SHCS did not have a higher rate of unsuppressed viral load than nonobese PWH.
Conclusions
The concentrations of ARVs are modestly reduced in obese individuals, with no negative impact on the virological response. Our data provide reassurance that standard doses of ARVs are suitable in obese PWH, including those who gained substantial weight with some of the first-line ARVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.
- Faculty of Medicine, University of Basel, Basel, Switzerland.
- Certara UK Limited, Sheffield, United Kingdom.
- Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland.
- Kantonsspital Baselland, University of Basel, Bruderholz, Switzerland.
- Service of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
ORCID-Profile: Catia Marzolini
Förderung
- Swiss National Foundation
Zitieren
APA
Berton, M., Bettonte, S., Stader, F., Decosterd, L., Tarr, P. E., Livio, F., Cavassini, M., Braun, D. L., Kusejko, K., Hachfeld, A., Bernasconi, E., Calmy, A., Schmid, P., Battegay, M., Marzolini, C., & Swiss HIV Cohort Study (2024). Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data. Clinical Infectious Diseases, 78(1), 98-110. https://doi.org/10.1093/cid/ciad495
Vancouver
Berton M, Bettonte S, Stader F, Decosterd L, Tarr PE, Livio F, et al. Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data. Clinical Infectious Diseases. 2024;78(1):98-110. doi:10.1093/cid/ciad495
BibTeX
@article{Berton2024,
author = {Berton, Mattia and Bettonte, Sara and Stader, Felix and Decosterd, Laurent and Tarr, Philip E and Livio, Françoise and Cavassini, Matthias and Braun, Dominique L and Kusejko, Katharina and Hachfeld, Anna and Bernasconi, Enos and Calmy, Alexandra and Schmid, Patrick and Battegay, Manuel and Marzolini, Catia and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
title = {Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data},
journal = {Clinical Infectious Diseases},
year = {2024},
volume = {78},
number = {1},
pages = {98--110},
doi = {10.1093/cid/ciad495}
}
EUVIMED